🇺🇸 FDA
Patent

US 9095608

Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody

granted A61KA61K2039/505A61K2039/55522

Quick answer

US patent 9095608 (Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody) held by The Regents of the University of Colorado expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado
Grant date
Tue Aug 04 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
66
CPC classes
A61K, A61K2039/505, A61K2039/55522, A61K38/00, A61K39/12